B. Riley Financial Varied
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aquestive Therapeutics Inc (NQ: AQST )

0.8101 +0.0001 (+0.01%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 21, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 901
Open 0.8101
Bid (Size) 0.7852 (13)
Ask (Size) 0.8200 (15)
Prev. Close 0.8100
Today's Range 0.8101 - 0.8101
52wk Range 0.6180 - 2.940
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Aquestive Therapeutics Reports Fourth Quarter & Full Year 2022 Financial Results and Provides Business Update on Key 2023 Objectives
From Aquestive Therapeutics, Inc.
Via Globe NewsWire
Earnings Outlook For Aquestive Therapeutics
 
Via Benzinga

Performance

YTD
-9.98%
-9.98%
1 Month
+1.93%
+1.93%
3 Month
-10.19%
-10.19%
6 Month
-27.67%
-27.67%
1 Year
-70.54%
-70.54%

More News

Read More
Aquestive Therapeutics to Participate in Oppenheimer 33rd Annual Healthcare Conference
From Aquestive Therapeutics, Inc.
Via Globe NewsWire
Aquestive Therapeutics to Report Fourth Quarter 2022 Financial Results and Recent Business Highlights on March 7 and Host Conference Call on March 8 at 8:00 a.m. ET
From Aquestive Therapeutics, Inc.
Via Globe NewsWire
Aquestive Inks Supply Pact For Its Seizure Treatment Covering European, Middle East Countries
Via Benzinga
Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies for AQST-109 Epinephrine Sublingual Film at American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting
From Aquestive Therapeutics, Inc.
Via Globe NewsWire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Aquestive Therapeutics Provides Business Update and Outlines Key 2023 Objectives
From Aquestive Therapeutics, Inc.
Via Globe NewsWire
Aquestive Therapeutics Announces Completion of FDA End-of-Phase 2 Meeting For AQST-109 (epinephrine sublingual film)
From Aquestive Therapeutics, Inc.
Via Globe NewsWire
Aquestive Therapeutics Announces Publication of Crossover Food Effect Study of Diazepam Nasal Spray in Epilepsia
From Aquestive Therapeutics, Inc.
Via Globe NewsWire
Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences
From Aquestive Therapeutics, Inc.
Via Globe NewsWire
Aquestive Therapeutics to Present Positive Data from Pharmacokinetic Studies for AQST-109 (epinephrine sublingual film) at American Academy of Allergy, Asthma, and Immunology (ACAAI) Annual Scientific Meeting
From Aquestive Therapeutics, Inc.
Via Globe NewsWire
Looking Into Aquestive Therapeutics's Return On Capital Employed
Via Benzinga
Aquestive Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
From Aquestive Therapeutics, Inc.
Via Globe NewsWire
Aquestive Therapeutics Earnings Preview
Via Benzinga
Aquestive Therapeutics Licenses Sympazan® (clobazam) Oral Film to Assertio Holdings, Inc.
From Aquestive Therapeutics, Inc.
Via Globe NewsWire
Aquestive Therapeutics Announces Positive Decision in States’ Suboxone Antitrust Lawsuit on All Claims
From Aquestive Therapeutics, Inc.
Via Globe NewsWire
Aquestive Therapeutics to Report Third Quarter 2022 Financial Results and Recent Business Highlights on November 1 and Host Conference Call on November 2 at 8:00 a.m. ET
From Aquestive Therapeutics, Inc.
Via Globe NewsWire
Aquestive Therapeutics Receives Positive FDA Written Response for AQST-109 Epinephrine Sublingual Film
From Aquestive Therapeutics, Inc.
Via Globe NewsWire
NASDAQ:AQST Investor Notice: Investigation over Potential Wrongdoing at Aquestive Therapeutics, Inc.
Via SBWire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Aquestive Therapeutics Enters License and Supply Agreement with Pharmanovia for Libervant™ (diazepam) Buccal Film for European and MENA Markets
From Aquestive Therapeutics, Inc.
Via Globe NewsWire
Why MindMed Is Trading Lower By Around 35%; Here Are 31 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Aquestive Therapeutics (AQST) Stock Gains on Positive Data for EpiPen Rival
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
B. Riley Financial's diverse suite of services goes beyond traditional financial service offerings. By leveraging cross-platform expertise and assets, B. Riley Financial companies are uniquely positioned to provide full service, collaborative solutions to our clients at every stage of the business life cycle and in all market conditions.

B. Riley refers to B. Riley Financial, Inc. and/or one or more of its subsidiaries or affiliates. Click here for further details.